This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Kite Pharma's Lead Program With The National Cancer Institute (NCI) Demonstrates Positive Results In Patients With Aggressive Non-Hodgkin's Lymphoma

LOS ANGELES, Dec. 7, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite's most advanced product candidate can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma.  In an oral presentation at the 55th ASH Annual Meeting, James N. Kochenderfer, MD, from the NCI reported that an infusion of patients' own genetically modified T lymphocytes resulted in six complete remissions (CR) and six partial remissions (PR) among 13 patients with advanced B-cell malignancies who were eligible for response assessment.


Kite Pharma and the Surgery Branch of the NCI, led by Steven A. Rosenberg, MD, PhD, are collaborating under a Cooperative Research and Development Agreement (CRADA) for the development and commercialization of novel eACT products for the treatment of multiple cancer indications.  This technology utilizes patients' peripheral blood T lymphocytes genetically engineered with either chimeric antigen receptors (CAR) or T cell receptors (TCR) that recognize tumor-specific molecules, traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors.  The reported Phase 1/2a clinical trial is being conducted at the NCI with Dr. Rosenberg serving as principal investigator.

In the clinical trial, patients' T cells were modified to express a CAR targeting the B cell antigen CD19.  Among the nine patients with either chemotherapy-refractory primary mediastinal B cell lymphoma (PMBCL) or diffuse large B cell lymphoma (DLBCL), seven patients were evaluable for response.  Of these seven patients, six showed a response (three CR's and three PR's).  This is the first report of successful treatment of these patients with CD19 CAR T cells.  The majority of clinical responses were durable (up to 22 months ongoing).  Acute toxicities, including fever, low blood pressure, focal neurological deficits, and delirium occurred in some patients after cell infusion, but resolved in less than three weeks.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs